Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
Breast Cancer
DRUG: Disitamab Vedotin|DRUG: RC148|DRUG: Albumin-bound Paclitaxone|DRUG: Toripalimab
ORR, The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1, 24 months
PFS, Progression-free survival is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first, From the first dose to the first documentation of disease progression or death, up to two years|DCR, The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1, 24 months|OS, OS is the time from randomization to death due to any cause safety, up to 5 years
Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer